Cell Therapeutics (CTIC) up 8.5% premarket as it announces the closing of its $60M convertible...

|About: CTI BioPharma Corp. (CTIC)|By:, SA News Editor

Cell Therapeutics (CTIC) up 8.5% premarket as it announces the closing of its $60M convertible preferred stock offering. The company got about $55.6M after expenses; each share of the Series 17 Preferred is convertible into about 714 shares of common stock at a $1.40/share conversion price. (previously)